Characterising people with focal drug-resistant epilepsy: A retrospective cohort study

Benoist, Caroline; Boccaletti, Simona; Leach, John Paul; Cattaneo, Agnese; Chaplin, Anna; Antunes, Luis; Heiman, Franca; Sander, Josemir W.

doi:10.1016/j.yebeh.2023.109540

Cited by 2 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other European countries reported similar findings: 51.4 years in Belgium, 50.7 years in Spain, 54.4 years in Italy, and 53.3 years in Germany, respectively [ 16 ]. For the overall study population, the mean age at focal DRE (F-DRE) diagnosis was 52.5 years as reported by Benoist et al [ 16 ]. The authors also report that “ similar demographics were seen across the six participating countries.…”

Section: Discussionsupporting

confidence: 55%

“…The average age at diagnosis reported in the study (mean 42.68 years) which, although may be perceived as high, is in line with other recent UK studies. For example, Benoist et al (2023)[ 16 ] report the mean age of 49 years for individuals with focal DRE in the UK. Other European countries reported similar findings: 51.4 years in Belgium, 50.7 years in Spain, 54.4 years in Italy, and 53.3 years in Germany, respectively [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…For example, Benoist et al (2023)[ 16 ] report the mean age of 49 years for individuals with focal DRE in the UK. Other European countries reported similar findings: 51.4 years in Belgium, 50.7 years in Spain, 54.4 years in Italy, and 53.3 years in Germany, respectively [ 16 ]. For the overall study population, the mean age at focal DRE (F-DRE) diagnosis was 52.5 years as reported by Benoist et al [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…In particular, a study of US veterans with DRE reported a mean age of 58.3. At the same time, a retrospective analysis of an Italian population found a mean age of 53 years for people with F-DRE [ 16 ] . ” The Benoist et al study reports on focal epilepsy, whereas the current study was all-inclusive.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021

Shankar,

Marston,

Danielson

et al. 2024

J Neurol

View full text Add to dashboard Cite

Background A third of people with epilepsy are drug resistant. People with drug-resistant epilepsy (DRE) have a higher risk of mortality and physical injuries than those who respond to anti-seizure medication (ASM). This study describes patient characteristics, comorbidities, and mortality in people with DRE in the UK. Methods The Clinical Practice Research Datalink was utilised to select people with DRE prescribed a third ASM between 1 January 2011 and 31 March 2021. Annual incidence and prevalence of DRE, patient characteristics, comorbidities, and mortality rates were analysed. Subgroup analysis was performed by age, sex, presence of intellectual disabilities and time from epilepsy diagnosis to DRE. Results A total of 34,647 people with DRE were included (mean ± SD age 42.68 ± 23.59 years, 52.6% females). During the study period, annual DRE incidence ranged from 1.99% to 3.12%. As of 31 March 2021, DRE prevalence was 26.6% (95% confidence interval [CI] 26.3%–26.8%). A greater proportion of people with DRE resided in the most deprived regions, with 21.1% and 16.7% in the top two quintiles of the Index of Multiple Deprivation respectively, compared to < 15% in the three less deprived regions. All-cause mortality ranged from 3,687 to 4,802 per 100,000 persons with DRE, four times higher than that in the general population in the UK. Variations existed across subgroups. Conclusions Considerable disease burden was observed in people with DRE in the UK. The findings emphasise the importance of early DRE diagnosis and appropriate disease management in people who develop DRE.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021

Shankar,

Marston,

Danielson

et al. 2024

J Neurol

View full text Add to dashboard Cite

show abstract

The Influence of Epilepsy on Oral Health Outcomes: A Retrospective Study in South Indian Adults

2024

Cureus

View full text Add to dashboard Cite

IntroductionEpilepsy, a chronic neurological disorder marked by recurrent seizures, affects approximately 50 million people worldwide with a higher prevalence in developing countries. This condition challenges motor skills and coordination, leading to poor oral health maintenance. The study aimed to evaluate the effect of epilepsy on oral health outcomes in adults by contrasting South Indian epileptics with healthy controls. The primary objective was to assess the prevalence of oral health issues in patients with epilepsy compared to healthy individuals and to analyze the types and frequency of dental procedures required in epileptic patients compared to healthy controls in the South Indian population.

show abstract

Characterising people with focal drug-resistant epilepsy: A retrospective cohort study

Cited by 2 publications

References 42 publications

Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021

Real-world evidence of epidemiology, patient characteristics, and mortality in people with drug-resistant epilepsy in the United Kingdom, 2011–2021

The Influence of Epilepsy on Oral Health Outcomes: A Retrospective Study in South Indian Adults

Contact Info

Product

Resources

About